Indian Bulk Drugs

Publication Date	July 2008
Publisher	Cygnus
Product Type	Report
Pages	183
ISBN Number	not applicable
Product Code	CYG00072

Price

£600.00
approximately: $895 | €715

OTHER ($895 | €715)

Order above formats by FAX

Summary

Introduction

The Indian API (bulk drugs) manufacturing industry is estimated to have touched USD4.10 billion by 2007, growing at CAGR of 18.81% during 2003* 07. India ranks fourth in terms of volume among the top 15 drug manufacturing countries. Cygnus releases the latest version of the Indian Bulk Drugs Industry Insight to capture the present domestic market scenario, along with the major players and their key financials

Key Findings & Highlights

The global pharmaceutical market was valued at USD712 billion in 2007.
According to IMS Health, treatment costs per day declined by 20* 40% in 2007 in therapy Areas
Generics continued to replace branded prescriptions in the major therapeutic classes, increasing their share of total dispensed prescriptions to 67.3 %.
In 2007, North America, which accounts for 45.9% of global pharmaceutical sales, grew by 4.2% to USD304.5 billion
The market size for the global bulk drugs was USD77.32 billion in 2005 and was estimated to be USD92.21 billion in 2007
Indian companies have the distinction of developing cost* effective technologies for manufacturing bulk drugs and intermediates that conform to global standards.

Reasons to Buy

Understand the global bulk drug market scenario
Know investment opportunities according to the trend analysis
Reveals the demand analysis of the bulk drugs industry
Assess the cost effective technologies for manufacturing bulk drugs.

Content

1. Executive Summary
2. Highlights
3. Global Bulk Drugs Market, Market Overview
- 3.1. Introduction
  - 3.1.1 Global Pharmaceutical Market
  - 3.1.2 Leading Therapeutic Classes
  - 3.1.3 Major Markets
- 3.2 Global Bulk Drugs Market
  - 3.2.1 Major Segments
  - 3.2.2 Classification Of Bulk Drugs Manufacturers
  - 3.2.3 Market Size
  - 3.2.4 Major Players
  - 3.2.5 Industry Trends
  - 3.2.6 Future Outlook
4. Indian Bulk Drugs Market-An Overview
- 4.1 Indian Pharmaceutical Market
- 4.1.1introduction
  - 4.1.2 Major Therapeutic Segments
- 4.2 Indian Bulk Drugs
  - 4.2.1 Introduction
  - 4.2.2 Market Size
  - 4.2.3 Major Bulk Drugs
  - 4.2.4 Industry Associations
    - 4.2.4.1 Bulk Drug Manufacturers' Association (India)
    - 4.2.4.2 Indian Drug Manufacturers Association (Idma)
    - 4.2.4.3 Organization Of Pharmaceutical Producers In India (Oppi)
- 4.3 Growth Trends
  - 4.3.1 Mergers & Acquisitions
  - 4.3.2 Indian Bulk Drugs Exports
  - 4.3.3 Indian Bulk Drugs Imports
- 4.4 Future Outlook
5. Growth Drivers
- 5.1 High Growth Of Generics / Patent Expiries
- 5.2 New Drug Developments
- 5.3 Contract Manufacturing
- 5.4 Overall Pharmaceutical Growth
- 5.5 Reduced Manufacturing Cost
6. Industry Regulations
- 6.1 Regulatory Bodies
- 6.2 Pharmaceutical Policy-2002
- 6.3 National Pharmaceutical Policy 2006
- 6.4 Pricing Of Scheduled Bulk Drugs
- 6.5 Indian Patent Law
- 6.6 Labelling System In India
- 6.7 Intellectual Property Rights (Ipr)
- 6.8 Trade Related Aspects Of Intellectual Property Rights (Trips)
- 6.9 Bulk Drugs Prices Come Under Nppa Lens
7. Issues & Challenges
- 7.1 Increasing Competition
- 7.2 Coping With Changing Disease Profile
- 7.3 Over Capacity
- 7.4 Undifferentiated Capabilities
- 7.5 Varying Regulatory Requirements Lead To Additional Costs
- 7.6 Threat From China
8. Major Players
- 8.1 Aurobindo Pharma
  - 8.1.1 Business Profile
  - 8.1.2 Strategies
  - 8.1.3 Financial Profile
  - 8.1.4 Swot Analysis
  - 8.1.5 Outlook
- 8.2 Ranbaxy Laboratories
  - 8.2.1 Business Profile
  - 8.2.2 Strategies
  - 8.2.3 Financial Profile
  - 8.2.4 Swot Analysis
  - 8.2.5 Outlook
- 8.3 Dr. Reddy's Laboratories
  - 8.3.1 Business Profile
  - 8.3.2 Strategies
  - 8.3.3 Financial Profile
  - 8.3.4 Swot Analysis
  - 8.3.5 Outlook
- 8.4 Lupin Ltd
  - 8.4.1 Business Profile
  - 8.4.2 Strategies
  - 8.4.3 Financial Profile
  - 8.4.4 Swot Analysis
  - 8.4.5 Outlook
- 8.5 Matrix Laboratories
  - 8.5.1 Business Profile
  - 8.5.2 Strategies
  - 8.5.3 Financial Profile
  - 8.5.4 Swot Analysis
  - 8.5.5 Outlook
- 8.6 Cipla Ltd
  - 8.6.1 Business Profile
  - 8.6.2 Strategies
  - 8.6.3 Financial Profile
  - 8.6.4 Swot Analysis
  - 8.6.5 Outlook
- 8.7 Orchid Chemicals And Pharmaceuticals Ltd
  - 8.7.1 Business Profile
  - 8.7.2 Strategies
  - 8.7.3 Financial Profile
  - 8.7.4 Swot Analysis
  - 8.7.5 Outlook
- 8.8 Divis Laboratories
  - 8.8.1 Business Profile
  - 8.8.2 Strategies
  - 8.8.3 Financial Profile
  - 8.8.4 Swot Analysis
  - 8.8.5 Outlook
- 8.9 Sun Pharmaceutical Industries Ltd
  - 8.9.1 Business Profile
  - 8.9.2 Strategies
  - 8.9.3 Financial Profile
  - 8.9.4 Swot Analysis
  - 8.9.5 Outlook
- 8.10 Ipca Laboratories Ltd
  - 8.10.1 Business Profile
  - 8.10.2 Strategies
  - 8.10.3 Financial Profile
  - 8.10.4 Swot Analysis
  - 8.10.5 Outlook
- 8.11 Dishman Pharmaceutical And Chemicals Ltd
  - 8.11.1 Business Profile
  - 8.11.2 Strategies
  - 8.11.3 Financial Profile
  - 8.11.4 Swot Analysis
  - 8.11.5 Outlook
- 8.12 Cadila Healthcare Ltd
  - 8.12.1 Business Profile
  - 8.12.2 Strategies
  - 8.12.3 Financial Profile
  - 8.12.4 Swot Analysis
  - 8.12.5 Outlook
- 8.13 Alembic Ltd
  - 8.13.1 Business Profile
  - 8.13.2 Strategies
  - 8.13.3 Financial Profile
  - 8.13.4 Swot Analysis
  - 8.13.5 Outlook
- 8.14. Glaxo Smithkline Pharmaceuticals Ltd
  - 8.14.1 Business Profile
  - 8.14.2 Strategies
  - 8.14.3 Financial Profile
  - 8.14.4 Swot Analysis
  - 8.14.5 Outlook
- 8.15 Glenmark Pharmaceuticals Ltd
  - 8.15.1 Business Profile
  - 8.15.2 Strategies
  - 8.15.3 Financial Profile
  - 8.15.4 Swot Analysis
  - 8.15.5 Outlook
- 8.16 Piramal Healthcare Limited (Phl)
  - 8.16.1 Business Profile
  - 8.16.2 Strategies
  - 8.16.3 Financial Profile
  - 8.16.4 Swot Analysis
  - 8.16.5 Outlook
- 8.17 Unichem Laboratories Ltd
  - 8.17.1 Business Profile
  - 8.17.2 Strategies
  - 8.17.3 Financial Profile
  - 8.17.4 Swot Analysis
  - 8.17.5 Outlook
- 8.18 Torrent Pharmaceuticals
  - 8.18.1 Business Profile
  - 8.18.2 Strategies
  - 8.18.3 Financial Profile
  - 8.18.4 Swot Analysis
  - 8.18.5 Outlook
- 8.19 Merck India Ltd
  - 8.19.1 Business Profile
  - 8.19.2 Strategies
  - 8.19.3 Financial Profile
  - 8.19.4 Swot Analysis
  - 8.19.5 Outlook
- 8.20 Atul Ltd
  - 8.20.1 Business Profile
  - 8.20.2 Strategies
  - 8.20.3 Financial Profile
  - 8.20.4 Swot Analysis
  - 8.20.5 Outlook
9. Critical Success Factors
- 9.1 Low- Cost Manufacturing Skills
- 9.2 Striking Strategic Alliances (Mergers & Acquisitions)
- 9.3 Growing Experience With Cgmp Compliance
- 9.4 Complex Synthesis Capabilities
- 9.5 Identifying New Opportunities Holds The Key For Generic Manufacturers
- 9.6 Indian Companies Enter In To Global Cancer Drugs Market
- 9.7 Focus On New Therapeutic Segments
- 9.8 Time The Market
- 9.9 Accreditations
10. Future Outlook
Annexure 1: List Of Abbreviations
Annexure 2: Dmf Filings By Indian Companies
Annexure 3: List Of Bulk Drugs Manufacturers In India
Annexure 4: List Of Industry Organizations
Annexure 5: Bibilography
List Of Charts
- Chart 1: Global Pharmaceutical Market Value, 2002-2007
- Chart 2: Market Share By Differentiation, 2007
- Chart 3: Global Bulk Drugs Market Size, 2003-2007
- Chart 4: Indian Pharmaceutical Market, 2002-2007
- Chart 5: Major Therapeutic Segments, 2006-2007
- Chart 6: Vision 2010: Glimpse Of Indian Pharmaceutical Market Future
- Chart 7: Estimated Indian Bulk Drugs Market
- Chart 8: Indian Pharmaceutical Exports
- Chart 9: Estimated Indian Bulk Drugs Exports
- Chart 10: Estimated Indian Bulk Drugs Imports
- Chart 11: Value Of Patent Expiries, 2006-2010
- Chart 12: Global Contract Manufacturing Market, 2002-2011
- Chart 13: India & China Dmf Filings
- Chart 14: Estimated Indian Bulk Drugs Market, 2006-2010e
- Chart 15: Estimated Indian Export And Import Trends, 2006-2010e
List Of Tables
- Table 1: Leading Therapeutic Segments, 2007
- Table 2: Leading Brands, 2007
- Table 3: Major Markets, 2007
- Table 4: Market Segment
- Table 5: Global Major Players
- Table 6: Global Mergers & Acquisition
- Table 7: Annual Production Of Major Bulk Drugs
- Table 8: Mergers & Acquisition By Indian Companies
- Table 9: Anda Filings By Indian Companies
- Table10: R&D Expenditure (2006-07)
- Table 11: Dmf Filings By Indian Companies
- Table 12: India's Advantages For Contract Manufacturing
- Table 13: Comparison Between India And China